Potential use of niosomal hydrogel as an ocular delivery system for atenolol

Biological and Pharmaceutical Bulletin

Volumn 37, Issue 4, 2014, Pages 541-551

  Hashim, Irhan Ibrahim Abu ^a   El dahan, Marwa Salah ^a   Yusif, Rehab Mohammed ^a   Abd ElGawad, Abd ElGawad Helmy ^a   Arima, Hidetoshi ^b  

^a MANSOURA UNIVERSITY   (Egypt)

^b KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Atenolol; Carbopol 934p; Glaucoma; Intraocular pressure; Niosomal hydrogel; Sustained release

Indexed keywords

ATENOLOL; CARBOPOL 934; NIOSOME; DELAYED RELEASE FORMULATION; HYDROGEL; LIPOSOME;

ADULT; ANALYZER; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG ACTIVITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RELEASE; ENCAPSULATION; GLAUCOMA; HYDROGEL; IN VITRO STUDY; INTRAOCULAR PRESSURE; LASER DIFFRACTION; MALE; MORPHOLOGY; NONHUMAN; PARTICLE SIZE; PHARMACODYNAMICS; TIME TO MAXIMUM PLASMA CONCENTRATION; TRANSMISSION ELECTRON MICROSCOPY; ADMINISTRATION AND DOSAGE; ANIMAL; DELAYED RELEASE FORMULATION; DRUG EFFECTS; DRUG STABILITY; INTRAOCULAR DRUG ADMINISTRATION; PHARMACOKINETICS; PROCEDURES; RABBIT; SYNTHESIS;

ADMINISTRATION, OPHTHALMIC; ANIMALS; ATENOLOL; DELAYED-ACTION PREPARATIONS; DRUG DELIVERY SYSTEMS; DRUG STABILITY; HYDROGEL; INTRAOCULAR PRESSURE; LIPOSOMES; MALE; PARTICLE SIZE; RABBITS;

EID: 84898745212     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.b13-00724     Document Type: Article

References (83)

1. Mundada AS, Shrikhande BK. Design and evaluation of soluble ocular drug insert for controlled release of ciprofloxacin hydrochloride. Drug Dev. Ind. Pharm., 32, 443-448 (2006).
2. Ali Y, Lehmussaari K. Industrial perspective in ocular drug delivery. Adv. Drug Deliv. Rev., 58, 1258-1268 (2006).
3. Wilson CG, Zhu YP, Frier M, Rao LS, Gilchrist P, Perkins AC. Ocular contact time of a carbomer gel (GelTears) in humans. Br. J. Ophthalmol., 82, 1131-1134 (1998).
4. Lee VH, Robinson JR. Topical ocular drug delivery: recent developments and future challenges. J. Ocul. Pharmacol., 2, 67-108 (1986).
5. Wei G, Xu H, Ding PT, Li SM, Zheng JM. Thermosetting gels with modulated gelation temperature for ophthalmic use: the rheological and gamma scintigraphic studies. J. Control. Release, 83, 65-74 (2002).
6. Arici MK, Arici DS, Topalkara A, Guler C. Adverse effects of topical antiglaucoma drugs on the ocular surface. Clin. Experiment. Ophthalmol., 28, 113-117 (2000).
7. Saettone MF, Giannaccini B, Chetoni P, Torracca MT, Monti D. Evaluation of high- and low-molecular-weight fractions of sodium hyaluronate and an ionic complex as adjuvants for topical ophthalmic vehicles containing pilocarpine. Int. J. Pharm., 72, 131-139 (1991).
8. Kumar S, Haglund BO, Himmelstein KJ. In situ-forming gels for ophthalmic drug delivery. J. Ocul. Pharmacol., 10, 47-56 (1994).
9. Sintzel MB, Bernatchez SF, Tabatabay C, Gurny R. Biomaterials in ophthalmic drug delivery. J. Pharm. Biopharm., 42, 358-374 (1996).
10. Abraham S, Furtado S, Bharath S, Basavaraj BV, Deveswaran R, Madhavan V. Sustained ophthalmic delivery of ofloxacin from an ion-activated in situ gelling system. Pak. J. Pharm. Sci., 22, 175-179 (2009).
11. Losa C, Alonso MJ, Vila JL, Orallo F, Martinez J, Saavedra JA, Pastor JC. Reduction of cardiovascular side effects associated with ocular administration of metipranolol by inclusion in polymeric nanocapsules. J. Ocul. Pharmacol., 8, 191-198 (1992).
12. Maurice DM. Prolonged-action drops. Int. Ophthalmol. Clin., 33, 81-91 (1993).
13. Nadkarni SR, Yalkowsky SH. Controlled delivery of pilocarpine. 1. In vitro characterization of Gelfoam matrices. Pharm. Res., 10, 109-112 (1993).
14. Davies NM, Farr SJ, Hadgraft J, Kellaway IW. Evaluation of mucoadhesive polymers in ocular drug delivery. II. Polymer-coated vesicles. Pharm. Res., 9, 1137-1144 (1992).
15. Kaur IP, Garg A, Singla AK, Aggarwal D. Vesicular systems in ocular drug delivery: an overview. Int. J. Pharm., 269, 1-14 (2004).
16. Vora B, Khopade AJ, Jain NK. Proniosome based transdermal delivery of levonorgestrel for effective contraception. J. Control. Release, 54, 149-165 (1998).
17. Uchegbu IF, Vyas SP. Non-ionic surfactant based vesicles (niosomes) in drug delivery. Int. J. Pharm., 172, 33-70 (1998).
18. Carafa M, Santucci E, Alhaique F, Coviello T, Murtas E, Riccieri FM, Lucania G, Torrisi MR. Preparation and properties of new unilamellar non-ionic/ionic surfactant vesicles. Int. J. Pharm., 160, 51-59 (1998).
19. Arunothayanun P, Bernard MS, Craig DQ, Uchegbu IF, Florence AT. The effect of processing variables on the physical characteristics of non-ionic surfactant vesicles (niosomes) formed from a hexadecyl diglycerol ether. Int. J. Pharm., 201, 7-14 (2000).
20. Resnikoff S, Pascolini D, Etya'ale D, Kocur I, Pararajasegaram R, Pokharel GP, Mariotti SP. Global data on visual impairment in the year 2002. Bull. World Health Organ., 82, 844-851 (2004).
21. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br. J. Ophthalmol., 90, 262-267 (2006).
22. Barrett AM, Carter J, Fitzgerald JD, Hull R, Le Count D. A new type of cardioselective adrenoceptive blocking drug. Br. J. Pharmacol., 48, 340P (1973).
23. Wettrell K, Pandolfi M. Effect of topical atenolol on intraocular pressure. Br. J. Ophthalmol., 61, 334-338 (1977).
24. Elliot MJ, Cullen PM, Phillips CI. Ocular hypotensive effect of atenolol (Tenormin, I.C.I.). A new beta-adrenergic blocker. Br. J. Ophthalmol., 59, 296-300 (1975).
25. Wettrell K, Pandolfi M. Effect of oral administration of various beta-blocking agents on the intraocular pressure in healthy volunteers. Exp. Eye Res., 21, 451-456 (1975).
26. Tutton MK, Smith RJ. Comparison of ocular hypotensive effects of 3 dosages of oral atenolol. Br. J. Ophthalmol., 67, 664-667 (1983).
27. Bellamy WT. P-glycoprotein and multidrug resistance. Annu. Rev. Pharmacol. Toxicol., 36, 161-183 (1996).
28. Yang JJ, Kim KJ, Lee VH. Role of P-glycoprotein in restricting propranolol transport in cultured rabbit conjunctival epithelial cell layers. Pharm. Res., 17, 533-538 (2000).
29. Holash JA, Stewart PA. The relationship of astrocyte-like cells to the vessels that contribute to the blood-ocular barriers. Brain Res., 629, 218-224 (1993).
30. Schlingemann RO, Hofman P, Klooster J, Blaauwgeers HG, Van der Gaag R, Vrensen GF. Ciliary muscle capillaries have blood-tissue barrier characteristics. Exp. Eye Res., 66, 747-754 (1998).
31. Wu J, Zhang JJ, Koppel H, Jacob TJ. P-glycoprotein regulates a volume activated chloride current in bovine non-pigmented ciliary epithelial cells. J. Physiol., 491, 743-755 (1996).
32. Saha P, Yang JJ, Lee VH. Existence of a P-glycoprotein drug efflux pump in cultured rabbit conjunctival epithelial cells. Invest. Oph thalmol. Vis. Sci., 39, 1221-1226 (1998).
33. Kawazu K, Yamada K, Nakamura M, Ota A. Characterization of cyclosporin A transport in cultured rabbit corneal epithelialcells: P-glycoprotein transport activity and binding to cyclophilin. Invest. Ophthalmol. Vis. Sci., 40, 1738-1744 (1999).
34. Dey S, Patel J, Anand BS, Jain-Vakkalagadda B, Kaliki P, Pal D, Ganapathy V, Mitra AK. Molecular evidence and functional expression of P-glycoprotein (MDR1) in human and rabbit cornea and corneal epithelial cell lines. Invest. Ophthalmol. Vis. Sci., 44, 2909-2918 (2003).
35. Dey S, Gunda S, Mitra AK. Pharmacokinetics of erythromycin in rabbit corneas after single-dose infusion: role of P-glycoprotein as a barrier to in vivo ocular drug absorption. J. Pharmacol. Exp. Ther., 311, 246-255 (2004).
36. Kallem R, Kulkarni CP, Patel D, Thakur M, Sinz M, Singh SP, Mahammad SS, Mandlekar S. A simplified protocol employing elacridar in rodents: a screening model in drug discovery to assess P-gp mediated efflux at the blood brain barrier. Drug Metab. Lett., 6, 134-144 (2012).
37. Phillips CI, Gore SM, Macdonald MJ, Cullen PM. Atenolol eye drops in glaucoma: a double-masked, controlled study. Br. J. Ophthalmol., 61, 349-353 (1977).
38. Brenkman RF. Long-term hypotensive effect of atenolol 4% eye-drops. Br. J. Ophthalmol., 62, 287-291 (1978).
39. Hassan MA. A long acting ophthalmic gel formulations of atenolol. Drug Dev. Ind. Pharm., 33, 1192-1198 (2007).
40. Baillie AJ, Florence AT, Hume LR, Muirhead GT, Rogerson A. The preparation and properties of niosomes-non-ionic surfactant vesicles. J. Pharm. Pharmacol., 37, 863-868 (1985).
41. Pardakhty A, Varshosaz J, Rouholamini A. In vitro study of polyoxyethylene alkyl ether niosomes for delivery of insulin. Int. J. Pharm., 328, 130-141 (2007).
42. Azeem A, Ahmad FJ, Khan ZI, Talegaonkar S. Non ionic surfactant vesicles as a carrier for transdermal delivery of frusemide. J. Dispers. Sci. Technol., 29, 723-730 (2008).
43. Mokhtar M, Sammour OA, Hammad MA, Megrab NA. Effect of some formulation parameters on flurbiprofen encapsulation and release rates of niosomes prepared from proniosomes. Int. J. Pharm., 361, 104-111 (2008).
44. Aggarwal D, Kaur IP. Improved pharmacodynamics of timolol maleate from a mucoadhesive niosomal ophthalmic drug delivery system. Int. J. Pharm., 290, 155-159 (2005).
45. Hu C, Rhodes DG. Proniosomes: a novel drug carrier preparation. Int. J. Pharm., 185, 23-35 (1999).
46. Winum JY, Casini A, Mincione F, Starnotti M, Montero JL, Scozzafava A, Supuran CT. Carbonic anhydrase inhibitors: N-(p-sulfamoylphenyl)-alpha-D- glycopyranosylamines as topically acting antiglaucoma agents in hypertensive rabbits. Bioorg. Med. Chem. Lett., 14, 225-229 (2004).
47. Monem AS, Ali FM, Ismail MW. Prolonged effect of liposomes encapsulating pilocarpine HCl in normal and glaucomatous rabbits. Int. J. Pharm., 198, 29-38 (2000).
48. Aburahma MH, Mahmoud AA. Biodegradable ocular inserts for sustained delivery of brimonidine tartarate: preparation and in vitro /in vivo evaluation. AAPS PharmSciTech, 12, 1335-1347 (2011).
49. El-Menshawe SF, Hussein AK. Formulation and evaluation of meloxicam niosomes as vesicular carriers for enhanced skin delivery. Pharm. Dev. Technol., 18, 779-786 (2013).
50. Abdelbary G, El-Gendy N. Niosome-encapsulated gentamicin for ophthalmic controlled delivery. AAPS PharmSciTech, 9, 740-747 (2008).
51. Ruckmani K, Sankar V. Formulation and optimization of Zidovudine niosomes. AAPS PharmSciTech, 11, 1119-1127 (2010).
52. El-Samaligy MS, Afifi NN, Mahmoud EA. Increasing bioavailability of silymarin using a buccal liposomal delivery system: preparation and experimental design investigation. Int. J. Pharm., 308, 140-148 (2006).
53. Attia IA, El-Gizawy SA, Fouda MA, Donia AM. Influence of a niosomal formulation on the oral bioavailability of acyclovir in rabbits. AAPS PharmSciTech, 8, 206-212 (2007).
54. Prabhu P, Nitish KR, Koland M, Harish N, Vijayanarayan K, Dhondge G, Charyulu R. Preparation and evaluation of nano-vesicles of brimonidine tartrate as an ocular drug delivery system. J. Young Pharm., 2, 356-361 (2010).
55. Seijo B, Fattal E, Roblot-Treupel L, Couvreur P. Design of nanoparticles of less than 50 nm diameter: preparation, characterization and drug loading. Int. J. Pharm., 62, 1-7 (1990).
56. Scholes PD, Coombes AGA, Illum L, Daviz SS, Vert M, Davies MC. The preparation of sub-200 nm poly(lactide- co -glycolide) microspheres for site-specific drug delivery. J. Control. Release, 25, 145-153 (1993).
57. Marianecci C, Paolino D, Celia C, Fresta M, Carafa M, Alhaique F. Non-ionic surfactant vesicles in pulmonary glucocorticoid delivery: characterization and interaction with human lung fibroblasts. J. Control. Release, 147, 127-135 (2010).
58. Aggarwal D, Garg A, Kaur IP. Development of topical niosomal preparation of acetazolamide: Preparation and evaluation. J. Pharm. Pharmacol., 56, 1509-1517 (2004).
59. El-Ridy MS, Abdelbary A, Nasr EA, Khalil RM, Mostafa DM, El-Batal AI, Abd El-Alim SH. Niosomal encapsulation of the antitubercular drug, pyrazinamide. Drug Dev. Ind. Pharm., 37, 1110-1118 (2011).
60. Yoshioka T, Sternberg B, Florence AT. Preparation and properties of vesicles (niosomes) of sorbitan monoesters (Span 20, 40, 60, 80) and a sorbitan triester (Span 85). Int. J. Pharm., 105, 1-6 (1994).
61. Glavas-Dodov M, Fredro-Kumbaradzi E, Goracinova K, Calis S, Simonoska M, Hincal AA. 5-Fluorouracil in topical liposome gels for anticancer treatment-formulation and evaluation. Acta Pharm., 53, 241-250 (2003).
62. Ning M, Guo Y, Pan H, Chen X, Gu Z. Preparation, in vitro and in vivo evaluation of liposomal/niosomal gel delivery systems for clotrimazole. Drug Dev. Ind. Pharm., 31, 375-383 (2005).
63. Türker S, Erdoǧan S, Ozer AY, Ergün EL, Tuncel M, Bilgili H, Deveci S. Scintigraphic imaging of radiolabelled drug delivery systems in rabbits with arthritis. Int. J. Pharm., 296, 34-43 (2005).
64. Durrani AM, Davies NM, Thomas M, Kellaway IW. Pilocarpine bioavailability from a mucoadhesive liposomal ophthalmic drug delivery system. Int. J. Pharm., 88, 409-415 (1992).
65. Pavelić Z, Skalko-Basnet N, Jalsenjak I. Liposomal gel with chloramphenicol: characterisation and in vitro release. Acta Pharm., 54, 319-330 (2004).
66. Barakat HS, Darwish IA, El-Khordagui LK, Khalafallah NM. Development of naftifine hydrochloride alcohol-free niosome gel. Drug Dev. Ind. Pharm., 35, 631-637 (2009).
67. Ritger PL, Peppas NA. A simple equation for description of solute release I. Fickian and non-fickian release from non-swellable devices in the form of slabs, spheres, cylinders or discs. J. Control. Release, 5, 23-36 (1987).
68. Korsmeyer RW, Gurny R, Doelker E, Buri PA, Peppas NA. Mechanisms of solute release from porous hydrophilic polymers. Int. J. Pharm., 15, 25-35 (1983).
69. Jadon PS, Gajbhiye V, Jadon RS, Gajbhiye KR, Ganesh N. Enhanced oral bioavailability of griseofulvin via niosomes. AAPS PharmSciTech, 10, 1186-1192 (2009).
70. Saettone MF, Perini G, Carafa M, Santucci E, Alhaique F. Nonionic surfactant vesicles as ophthalmic carriers for cyclopentolate: a preliminary evaluation. STP Pharma, 6, 94-98 (1996).
71. Guinedi AS, Mortada ND, Mansour S, Hathout RM. Preparation and evaluation of reverse-phase evaporation and multilamellar niosomes as ophthalmic carriers of acetazolamide. Int. J. Pharm., 306, 71-82 (2005).
72. van Abbé NJ. Eye irritation: studies relating to responses in man and laboratory animals. J. Soc. Cosmet. Chem., 24, 685-692 (1973).
73. North-Root H, Yackovich F, Demetrulias J, Gacula M Jr, Heinze JE, Gacula M Jr. Prediction of the eye irritation potential of shampoos using the in vitro SIRC cell toxicity test. Food Chem. Toxicol., 23, 271-273 (1985).
74. Cheong HI, Johnson J, Cormier M, Hosseini K. In vitro cytotoxicity of eight beta-blockers in human corneal epithelial and retinal pigment epithelial cell lines: comparison with epidermal keratinocytes and dermal fibroblasts. Toxicol. In Vitro, 22, 1070-1076 (2008).
75. Shaikh K, Pawar A, Aphale S, Moghe A. Effect of vesicular encapsulation on in-vitro cytotoxicity of ciclopirox olamine. Int. J. Drug Deliv., 4, 139-146 (2012).
76. Zarei M, Norouzian D, Honarvar B, Mohammadi M, Ebrahimi Shamabadi H, Akbarzadeh A. Paclitaxel loaded niosome nanoparticle formulation prepared via reverse phase evaporation method: an in vitro evaluation. Pak. J. Biol. Sci., 16, 295-298 (2013).
77. Sugrue MF. The preclinical pharmacology of dorzolamide hydrochloride, a topical carbonic anhydrase inhibitor. J. Ocul. Pharmacol. Ther., 12, 363-376 (1996).
78. Ponticello GS, Sugrue MF, Plazonnet B, Durand-Cavagna G. Dorzolamide, a 40-year wait. From an oral to a topical carbonic anhydrase inhibitor for the treatment of glaucoma. Pharm. Biotechnol., 11, 555-574 (1998).
79. Aggarwal D, Pal D, Mitra AK, Kaur IP. Study of the extent of ocular absorption of acetazolamide from a developed niosomal formulation, by microdialysis sampling of aqueous humor. Int. J. Pharm., 338, 21-26 (2007).
80. Abdelkader H, Wu Z, Al-Kassas R, Alany RG. Niosomes and discomes for ocular delivery of naltrexone hydrochloride: Morphological, rheological, spreading properties and photo-protective effects. Int. J. Pharm., 433, 142-148 (2012).
81. El-Gazayerly ON, Hikal AH. Preparation and evaluation of acetazolamide liposomes as an ocular delivery system. Int. J. Pharm., 158, 121-127 (1997).
82. Rosenlund EF. The intraocular pressure lowering effect of timolol in gel-forming solution. Acta Ophthalmol. Scand., 74, 160-162 (1996).
83. Hosny KM. Ciprofloxacin as ocular liposomal hydrogel. AAPS PharmSciTech, 11, 241-246 (2010).